Texas is currently home to 4871 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of the Integrated Smart Pump-EHR Technology in Eight Adult Acute and Intensive Care Units
Recruiting
This study looks at the effects of using "smart pumps" that connect with the Electronic Health Record (EHR) in 8 adult ICU units. We will interview nurses and healthcare team members to learn about any challenges with this technology. All nurses in these units will be invited to complete a survey on how easy the technology is to use. Some nurses will practice giving medications to "mannequins" in a simulation lab to see how they work with the pumps. We will also look at existing data to find... Read More
Gender:
ALL
Ages:
20 years and above
Trial Updated:
02/27/2025
Locations: University Health, San Antonio, Texas
Conditions: Nurse's Role
A Study of LY4005130 in Healthy Participants
Recruiting
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4005130 gets into the bloodstream and how long it takes the body to eliminate it. Part A for the single-ascending doses (SAD) of the study will last about 12 weeks with 9 visits. Part B for t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/27/2025
Locations: Fortrea Clinical Research Unit, Dallas, Texas
Conditions: Healthy
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
Recruiting
To evaluate the antitumor efficacy of intralesional injections of nivolumab in patients with high-risk oral premalignant lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Premalignant Lesion
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
Recruiting
The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoeducational support group and an implementation/communication skills training phase on measures of psychosocial function, communicative effectiveness and speech/language function. Analysis of study-speci... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: University of Texas at Austin, Austin, Texas
Conditions: Alzheimer Disease, Dementia, Primary Progressive Aphasia, Aphasia, Progressive Aphasia, Progressive Aphasia in Alzheimer's Disease
Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis
Recruiting
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Zydus US004, Houston, Texas
Conditions: Primary Biliary Cholangitis
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
Recruiting
To find the highest safe dose of ziftomenib that can be combined with venetoclax and azacitidine in pediatric participants with acute leukemia that has certain types of genetic mutations (changes).
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
02/27/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Refractory Acute Leukemia, Pediatric Relapsed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: AARA Research Center, Dallas, Texas
Conditions: Perennial Allergic Rhinitis (PAR)
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Recruiting
This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC)
A Study of MGC026 in Participants With Advanced Solid Tumors
Recruiting
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer
A Study of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Recruiting
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer, Solid Tumor
Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED
Recruiting
Adult subjects with mild to moderate and moderate ED who meet the study eligibility criteria will be enrolled in the study. The enrolled subjects will be randomized by a 1:1 ratio to receive the Active or Sham VERTICA® treatment. Baseline assessments will include collection of demographic data, medical history, concomitant medications and baseline clinical examinations. The initial treatment session will be performed in a clinical setting simulating home use to determine proper device use and to... Read More
Gender:
MALE
Ages:
Between 22 years and 85 years
Trial Updated:
02/27/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Erectile Dysfunction
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Recruiting
CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: MD Anderson, Houston, Texas
Conditions: Advanced Solid Tumor